Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients

Germans Trias i Pujol Hospital126 enrolled

Overview

To evaluate the therapeutic equivalence between the two arms of treatment in virological and immunological response after 48 weeks and to evaluate the presence of side effects during the follow-up period.

The efficacy of the highly active antiretroviral treatment (HAART) has been demonstrated in several clinical trials. Even so, a substantial proportion of patients do not manage to maintain correct viral suppression in daily clinical practice. Adherence to HAART treatment is critical to obtain lasting viral suppression. Thus, factors that are related to adherence such as high pill load or takes, the complexity of the antiretroviral system, tolerability and food restrictions may have an effect on viral replication. It has been demonstrated that simpler regimens with a scant number of tablets, without food restrictions and with a single take a day are safe, efficacious and that adherence improves. The combination of abacavir 600 mg + lamivudine 300 mg QD in a single tablet is a novel dosage that may help increase treatment adherence.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

126

Conditions

HIV Infections

Interventions

KivexaDRUG

abacavir 600mg + lamivudine 300mg in one tablet QD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age\> 18 years. 2. HIV-1 infected patients. 3. Naive to antiretroviral treatment. 4. Candidate patient for initiating antiretroviral treatment\*. 5. Subject able to follow the treatment period. 6. Signature of the informed consent. 7. Women may not be fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use two contraceptive methods during the study, one of them at least being a barrier method. Exclusion Criteria: 1. Hepatic tests \> 5 times above normality. 2. Pregnancy or breastfeeding. 3. Treatment for opportunistic infections or neoplasms associated with the stable HIV over the last 6 weeks. 4. Suspected or documented resistance to any of the investigational drugs. 5. Known allergic hypersensitivity to any of the investigational drugs or any similar drug. 6. Subjects with abusive consumption of alcohol or illegal drugs. 7. Patients participating in another clinical trial. 8. Terminal renal disease.

Locations (20)

Institute of Infections and Tropical Diseases University of Brescia

Brescia, Italy

Hospital Arquitecto Marcide

Ferrol, A Coruña, Spain

Outcomes

Primary Outcomes

To evaluate the virological response over the 48 weeks of the study.

Time frame: At 12, 24, 36 and 48 weeks

Secondary Outcomes

To evaluate the immunological efficacy (changes in CD4 and CD8 counts) of the combination studied over the follow-up period.

Time frame: At 12, 24, 36 and 48 weeks.

To evaluate the impact of treatment on the lipid profile.

Time frame: At 12, 24, 36 and 48 weeks

To evaluate the tolerance and safety of the combination of Efavirenz + lamivudine + abacavir given once daily over the 48-week treatment period.

Time frame: At 12, 24, 36 and 48 weeks.

To evaluate treatment adherence (assessed by a self-reported questionnaire and with graduated satisfaction scales) and patient quality of life (assessed by means of the MOS-HIV questionnaire).

Time frame: At 12, 24, 36 and 48 weeks.

To analyse the mutations that appear in patients that present virological failure.

Time frame: When there is a virological failure.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.